Drug Profile
Interleukin-1-alpha - Dainippon Sumitomo Pharma/Roche
Alternative Names: Interleukin-1-alpha - Dainippon Sumitomo Pharma; rIL-1 alphaLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Dainippon Sumitomo Pharma; National Cancer Institute (USA)
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 1-alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 05 Jun 2001 Discontinued-Clinical for Malignant melanoma in Japan (Intralesional)
- 05 Jun 2001 Discontinued-Clinical for Non-small cell lung cancer in Japan (Unknown route)